1. Report Overview

1.1 Why You Should Read This Report

1.2 How This Report Delivers

1.3 Key Questions Answered by This Analytical Report

1.4 Who is This Report For?

1.5 Methodology

1.5.1 Primary Research

1.5.2 Secondary Research

1.5.3 Market Evaluation & Forecasting Methodology

1.6 Frequently Asked Questions (FAQ)

1.7 Associated Visiongain Reports

1.8 About Visiongain

2. Introduction to Epilepsy

2.1 What are Seizures?

2.2 What is status epilepticus?

2.2.1 Types of Seizures

2.2.1.1 Onset of Seizures

2.2.1.2 Level of Awareness

2.2.1.3 Presence or Absence of Motor Symptoms

2.3 Epilepsy Syndrome

2.4 What Are the Risk Factors for Epilepsy?

2.4.1 Age

2.4.2 Head injuries

2.4.3 Family History

2.4.4 Childhood Seizures

2.4.5 Infections

2.4.6 Dementia and Vascular Diseases

2.4.7 Administration of Drugs

2.5 What Are the Various Complications Associated with Epilepsy?

2.5.1 Increased Likelihood of Road Accidents

2.5.2 Increased Risk of Falls and Drowning while Swimming

2.5.3 Complications during Pregnancy

2.5.4 Impairment of Mental Health and Social Stigma Associated with the Disease

2.5.5 Status Epilepticus

2.5.6 Sudden Unexplained Death in Epilepsy (SUDEP)

2.6 Diagnosis of Epilepsy

2.6.1.1 Electroencephalogram (EEG)

2.6.1.2 Neuroimaging

2.6.1.3 Other Tests

2.6.1.4 Neuropsychological Assessment

2.7 Epidemiology of Epilepsy

2.7.1 Incidence

2.7.2 Prevalence

2.7.2.1 Epidemiology by Country

2.7.2.2 Historical Prevalence in G7 Markets

2.7.2.3 Forecast of Epilepsy in G7 Markets 2016-2027

2.8 Humanistic and Economic Burden

2.8.1 Mortality

2.8.1.1 Mortality in the US

2.8.1.2 Mortality in the UK

2.8.2 HRQoL

2.8.3 Economic Impact

2.8.3.1 Direct and Indirect Costs of Caregiving

2.9 Epilepsy: Treatment

2.9.1 Pharmacotherapy

2.9.2 Psychological Interventions

2.9.3 Dietary Modifications

2.9.4 Vagus Nerve Stimulation (VNS)

2.9.5 Epilepsy Surgery

2.9.6 Deep Brain Stimulation (DBS)

2.9.7 Responsive Neurostimulation System (RNS)

3. Introduction to the Anti-Epilepsy Drugs Market

3.1 Market Definition and Scope

3.2 Market Drivers, Challenges, and Trends

3.2.1 Market Drivers

3.2.1.1 Unmet Medical Need

3.2.1.2 Increase in Patient Population

3.2.1.3 Research Funding and Awareness

3.2.2 Market Challenges

3.2.2.1 Market Entry of Generic Drugs

3.2.2.2 Social Stigma Associated with Neurological Disorders

3.2.3 Market Trends

3.2.3.1 Reformulation and Indication Expansion

3.2.3.2 Emergence of New-generation of AEDs

4. Global Anti-Epilepsy Drugs Market 2016

4.1 Global Anti-Epilepsy Drugs Market Forecast 2017-2027

4.1 Market Segmentation by Generation of Drugs

4.1.1 Global Anti-Epilepsy Drugs Submarkets Forecast 2017-2027

4.1.1.1 Global Anti-Epilepsy First Generation Drugs Market Forecast 2017-2027

4.1.1.2 Global Anti-Epilepsy Second Generation Drugs Market Forecast 2017-2027

4.1.1.3 Global Anti-Epilepsy Third Generation Drugs Market Forecast 2017-2027

4.1.1.4 Global Anti-Epilepsy Other Drugs Market Forecast 2017-2027

5. Global Anti-Epilepsy Drugs - Market Players

5.1 Historical Market Share

5.2 Current Market Leaders

5.2.1 UCB

5.2.1.1 Vimpat

5.2.1.2 Keppra

5.2.1.3 Briviact

5.2.2 GlaxoSmithKline

5.2.2.1 Lamictal

5.2.2.2 Potiga / Trobalt

5.2.3 Pfizer

5.2.3.1 Lyrica

5.2.3.2 Neurontin

6. Leading National Markets Forecast 2017-2027

6.1 Geographical Breakdown of Global Anti-Epilepsy Drugs Market, 2016

6.2 Anti-Epilepsy Drugs Market Forecast by Region 2017-2027

6.3 Anti-Epilepsy Drugs Market in the US, 2016

6.3.1 Market Forecast of the US, 2017-2027

6.4 Anti-Epilepsy Drugs Market in EU5, 2016

6.4.1 Market Forecast of EU5, 2017-2027

6.5 Anti-Epilepsy Drugs Market in the BRIC, 2016

6.5.1 Market Forecast of the BRIC, 2017-2027

6.6 Anti-Epilepsy Drugs Market in Japan, 2016

6.6.1 Market Forecast of the Japan, 2017-2027

6.7 Anti-Epilepsy Drugs Market in RoW, 2016

6.7.1 Market Forecast of the RoW, 2017-2027

7. Pricing and Reimbursement Overview

7.1 NICE

7.2 SMC

7.3 HAS

7.4 Canada

7.5 Italy

7.6 United States

7.7 Australia

7.8 G-BA/IQWIG

8. Active Pipeline Molecules

8.1 Overall Pipeline Status and Promising Candidates

8.1.1 Everolimus

8.1.2 Lyrica Controlled-release

8.1.3 Briviact

8.1.4 Vimpat

8.1.5 E2007

8.1.6 SAGE-547

8.1.7 Epidiolex

8.1.8 Cenobamate

8.1.9 ZX008

8.1.10 Ganaxolone

8.1.11 Immunoglobulin, normal (human)

8.1.12 USL261

8.1.13 Alprazolam

8.1.14 Ataluren

8.1.15 GWP42006

8.1.16 PF-062372865

8.1.17 UCB-0942 and UCB-3491

8.1.18 BGG-492

8.1.19 PRX00023

8.2 Novel Mechanism of Action

9. Conclusions

Glossary

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain report evaluation form

List of Tables

Table 1.1 Example of Global Anti-Epilepsy Drugs Market by Regional Market Forecast 2017-2027 ($m, AGR %, Cumulative)

Table 2.1 Type of Focal Seizures

Table 2.2 Type of Unknown-onset Seizures

Table 2.3 Prevalence of Epilepsy, all ages, all types, rates per 1,000 population per year

Table 2.4 Diagnosed Prevalence (absolute cases) of Epilepsy in G7 Markets, 2016

Table 2.5 Forecast of Diagnosed Prevalence of Epilepsy in G7 Markets: AGR (%), CAGR (%), 2016-2027

Table 2.6 Forecast of Diagnosed Prevalence of Epilepsy in the US: AGR (%), CAGR (%), 2016-2027

Table 2.7 Forecast of Diagnosed Prevalence of Epilepsy in France: AGR (%), CAGR (%), 2016-2027

Table 2.8 Forecast of Diagnosed Prevalence of Epilepsy in Germany: AGR (%), CAGR (%), 2016-2027

Table 2.9 Forecast of Diagnosed Prevalence of Epilepsy in the UK: AGR (%), CAGR (%), 2016-2027

Table 2.10 Forecast of Diagnosed Prevalence of Epilepsy in Italy: AGR (%), CAGR (%), 2016-2027

Table 2.11 Forecast of Diagnosed Prevalence of Epilepsy in Spain: AGR (%), CAGR (%), 2016-2027

Table 2.12 Forecast of Diagnosed Prevalence of Epilepsy in Japan: AGR (%), CAGR (%), 2016-2027

Table 2.13 Healthcare Utilization Rates by Caregivers of Individuals Suffering from Epilepsy vs General Population

Table 2.14 Direct and Indirect Costs for the General Population and Caregivers of Persons with Epilepsy (in US$)

Table 4.1 Global Anti-Epilepsy Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 4.2 List of some of the Approved AEDs

Table 4.3 Global Anti-Epilepsy Drugs Markets by Segmentation: Revenue ($m), and Market Share (%), 2016

Table 4.4 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 4.5 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs 2016-2027: AGR (%)

Table 4.6 Global Anti-Epilepsy First Generation Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 4.7 Global Anti-Epilepsy Second Generation Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 4.8 Global Anti-Epilepsy Third Generation Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 4.9 Global Anti-Epilepsy Other Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 5.1 Product Portfolio of UCB

Table 5.2 Vimpat Key Milestones

Table 5.3 Keppra / Keppra XR Key Milestones

Table 5.4 Briviact Key Milestones

Table 5.5 Product Portfolio of Pfizer

Table 6.1 Anti-Epilepsy Drugs Market by Region: Revenue ($m), and Market Share (%), 2016

Table 6.2 Anti-Epilepsy Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%),2016-2027

Table 6.3 Anti-Epilepsy Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 6.4 Anti-Epilepsy Drugs Market Forecast in EU5 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 6.5 Anti-Epilepsy Drugs Market Forecast in BRIC 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 6.6 Anti-Epilepsy Drugs Market Forecast in Japan 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 6.7 Anti-Epilepsy Drugs Market Forecast in RoW 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 8.1 Active Pipeline Molecules under Development for Treating Epilepsy

List of Figures

Figure 1.1 Example of Global Anti-Epilepsy Drugs Market by Regional Market Share Forecast 2017, 2022, 2027(% Share)

Figure 2.1 Types of Generalized Seizures

Figure 2.2 Diagnosed Prevalence (absolute cases) of Epilepsy in G7 Markets, 2016

Figure 2.3 Diagnosed Prevalence (%) of Epilepsy in G7 Markets, 2016

Figure 2. 4 Historical Prevalence of Epilepsy in G7 Markets: CAGR (%), 2011-2015

Figure 2.5. Historical Diagnosed Prevalence of Epilepsy in G7 Markets: Share (%) of Absolute cases, 2011-2015

Figure 2.6 Forecast of Diagnosed Prevalence of Epilepsy in the US: AGR (%), CAGR (%), 2016-2027

Figure 2.7 Forecast of Diagnosed Prevalence of Epilepsy in France: AGR (%), CAGR (%), 2016-2027

Figure 2.8 Forecast of Diagnosed Prevalence of Epilepsy in Germany: AGR (%), CAGR (%), 2016-2027

Figure 2.9 Forecast of Diagnosed Prevalence of Epilepsy in the UK: AGR (%), CAGR (%), 2016-2027

Figure 2.10 Forecast of Diagnosed Prevalence of Epilepsy in Italy: AGR (%), CAGR (%), 2016-2027

Figure 2.11 Forecast of Diagnosed Prevalence of Epilepsy in Spain: AGR (%), CAGR (%), 2016-2027

Figure 2.12 Forecast of Diagnosed Prevalence of Epilepsy in Japan: AGR (%), CAGR (%), 2016-2027

Figure 2.13 Epilepsy and Status Epilepticus Related Deaths in the US, 2015

Figure 2.14 Epilepsy and Status Epilepticus Related Deaths in the US, 2013 – 2015

Figure 2.15 Epilepsy and Status Epilepticus Related Deaths in the UK, 2015

Figure 2.16 Epilepsy Related Deaths in the UK, 2013 – 2015

Figure 2.17 Percentage of Adults with and Without Epilepsy Who Have Difficulty Getting Health Care

Figure 2.18Treatment Algorithm of Epilepsy using Pharmacotherapies

Figure 2.19 Pharmacotherapy for Seizures

Figure 2.20Treatment Algorithm of Status Epilepticus using Pharmacotherapies

Figure 4.1 Global Anti-Epilepsy Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)

Figure 4.2: Epilepsy Market Segmentation by Generation of Drugs

Figure 4.3 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs: Revenue ($m), 2016

Figure 4.4 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs: Market Share (%), 2016

Figure 4.5 Global Anti-Epilepsy Drugs Market by Generation of Drugs 2016-2027: Revenue ($m), Global AGR (%)

Figure 4.6 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs: Revenue ($m), CAGR (%), 2016 & 2027

Figure 4.7 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs 2016-2027: AGR (%)

Figure 4.8 Global Anti-Epilepsy First Generation Drugs Market 2016-2027: Revenue ($m), AGR (%)

Figure 4.9 Global Anti-Epilepsy Second Generation Drugs Market 2016-2027: Revenue ($m), AGR (%)

Figure 4.10 Global Anti-Epilepsy Third Generation Drugs Market 2016-2027: Revenue ($m), AGR (%)

Figure 4.11 Global Anti-Epilepsy Other Drugs Market 2016-2027: Revenue ($m), AGR (%)

Figure 5.1 Market Share of AEDs, in 2008

Figure 5.2 Vimpat Revenue 2011-2016 (US$ million)

Figure 5.3 Vimpat Sales by Geographical Segmentation, 2016

Figure 5.4 Vimpat Forecasted Revenue 2017-2022 (US$ million)

Figure 5.5 Market Growth of Vimpat in the US and EU (in 2016)

Figure 5.6 Keppra/Keppra XR Revenue 2011-2016 (US$ million)

Figure 5.7 Keppra/Keppra XR Sales by Geographical Segmentation 2016

Figure 5.8 Keppra/Keppra XR Forecasted Revenue 2017-2022 (US$ million)

Figure 5.9 Market Growth of Keppra/Keppra XR in the US and EU (in 2016)

Figure 5.10 Briviact Sales by Geographical Segmentation 2016

Figure 5.11 Briviact Forecasted Revenue 2017-2022 (US$ million)

Figure 5.12 Lamictal Revenue 2011-2016 (US$ million)

Figure 5.13 Lamictal Sales by Geographical Segmentation 2016

Figure 5.14 Lyrica Revenue 2011-2016 (US$ million)

Figure 5.15 Neurontin Revenue 2011-2016 (US$ million)

Figure 6.1 Anti-Epilepsy Drugs Market Segmentation by Region/Country

Figure 6.2 Anti-Epilepsy Drugs Market by Region: Revenue ($m)

Figure 6.3 Anti-Epilepsy Drugs Market by Region: Market Share 2016 (%)

Figure 6.4 Global Anti-Epilepsy Drugs Market in the US: Market Share (%), 2016

Figure 6.5 Anti-Epilepsy Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%)

Figure 6.6 Anti-Epilepsy Drugs Market in the EU5: Market Share (%), 2016

Figure 6.7 Anti-Epilepsy Drugs Market Forecast in EU5 2016-2027: Revenue ($m), AGR (%)

Figure 6.8 Anti-Epilepsy Drugs Market in BRIC: Market Share (%), 2016

Figure 6.9 Anti-Epilepsy Drugs Market Forecast in BRIC 2016-2027: Revenue ($m), AGR (%)

Figure 6.10 Anti-Epilepsy Drugs Market in Japan: Market Share (%), 2016

Figure 6.11 Anti-Epilepsy Drugs Market Forecast in Japan 2016-2027: Revenue ($m), AGR (%)

Figure 6.12 Anti-Epilepsy Drugs Market Forecast in RoW 2016-2027: Revenue ($m), AGR (%)

Figure 8.1 Share of Pipeline Molecules by Phase of Development

Figure 8.2 Status of Patent Protection of Afinitor (excludes patent on cancer indications

Figure 9.1 Global Anti-Epilepsy Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)

Figure 9.2 Anti-Epilepsy Drugs Market by Region: Revenue ($m)